Innate Pharma (IPHYF) Earns “Buy” Rating from HC Wainwright
Shares of Innate Pharma (OTC IPHYF) opened at 12.96 on Wednesday. The company’s 50 day moving average price is $12.54 and its 200-day moving average price is $12.40. The firm has a market capitalization of $699.74 million and a P/E ratio of 48.18. Innate Pharma has a 12 month low of $10.72 and a 12 month high of $16.55.
TRADEMARK VIOLATION WARNING: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/01/innate-pharma-iphyf-earns-buy-rating-from-hc-wainwright.html.
Receive News & Stock Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related stocks with our FREE daily email newsletter.